Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enovis Corporation filings document the formal disclosures of a public medical technology company with Reconstructive and Prevention & Recovery operations. Recent Form 8-K reports cover quarterly and annual results, furnished earnings releases, conference presentation materials and Regulation FD disclosures tied to management presentations.
The filing record also includes proxy materials for annual meeting governance, board and executive compensation matters, executive transition disclosures, and material financing agreements. Enovis filings describe credit facilities, leverage covenants, guarantor arrangements, senior unsecured convertible notes references, financial condition, segment performance and related risk and governance subjects.
Enovis Corporation Schedule 13G/A amendment discloses beneficial ownership positions held by American Century entities and Stowers Institute. The filing lists American Century Investment Management, Inc. and American Century Companies, Inc. each holding 6,106,561 shares (10.6%), and American Century Capital Portfolios, Inc. holding 2,689,128 shares (4.7%), as reported on the cover pages. The registrants state their principal business address and identify voting and dispositive powers for each holder. The filing is an ownership disclosure amendment signed on 07/08/2026.
Ortiz Christine reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Christine Ortiz received an equity award of 846 shares of common stock. The shares were granted on June 30, 2026 at a stated price of $0.00 per share as a compensation-related award rather than a market purchase.
Following this grant, Ortiz directly holds 25,857 shares of Enovis common stock. This filing records a routine non-derivative stock award to a board member, with no associated open-market buying or selling activity.
Enovis CORP Chief Administrative Officer Oliver Engert reported an open-market purchase of 1,000 shares of common stock at $20.92 per share. Following this transaction, he directly owns 53,640 shares of Enovis common stock, increasing his personal stake in the company.
Engert Oliver reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp Chief Administrative Officer Oliver Engert reported an amended insider transaction showing a grant of 1,000 shares of common stock at $20.99 per share. The filing updates his direct holdings to 52,640 shares. The amendment corrects clerical errors in the original Form 4; no other changes were made.
Enovis CORP Chief Administrative Officer Oliver Engert bought additional company stock in the open market. He made two open-market purchases of Enovis common stock, totaling 1,200 shares. One trade was for 1,000 shares at $21.75 per share and another for 200 shares at $20.99 per share. These are direct ownership purchases, indicating he increased his personal stake in the company.
Enovis CORP Chief Administrative Officer Oliver Engert bought 1,000 shares of common stock in an open-market purchase at $23.00 per share on June 10, 2026. After this transaction, he directly owns 50,640 Enovis shares, modestly increasing his personal stake in the company.
Enovis CORP Chief Administrative Officer Oliver Engert purchased additional company stock in the open market. He bought 1,000 shares of common stock at a price of $22.22 per share. After this transaction, he directly owns a total of 49,640 shares of Enovis common stock.
Shirley Brady reported acquisition or exercise transactions in this Form 4 filing.
Enovis CORP director Shirley Brady received a grant of 9,346 shares of common stock on May 19, 2026. The shares were awarded at no stated price as compensation rather than a market purchase. After this award, Brady directly holds a total of 110,589 Enovis common shares.
Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.
Enovis Corp director Barbara W. Bodem received an equity award of 9,346 shares of common stock on May 19, 2026. The shares were granted at no cash cost to her, reflecting stock-based compensation rather than an open-market purchase. After this award, she directly owns 24,201 Enovis common shares.
Enovis CORP director Philip Okala received a grant of 9,346 shares of common stock. The award was recorded on May 19, 2026 at a stated price of $0.00 per share, indicating it was a compensation-related equity grant rather than an open-market purchase.
After this grant, Okala directly holds a total of 24,201 shares of Enovis common stock. The filing does not show any share sales, option exercises, or derivative positions; it only reports this single stock award and the resulting direct ownership level.